Unlike injectable GLP-1 receptor agonists, Rybelsus offers patients who are needle-averse or prefer not to inject a viable treatment option
Valdes A M, Walter J, Segal E, Spector T D
Regor Therapeutics RGT-075 RGT-075 is a once-daily oral small-molecule GLP-1 receptor full agonist being developed by Regor for the treatment of metabolic disorders such as type 2 diabetes mellitus, obesity, and overweight conditions linked with weight-related comorbidities
You can inject at the 12 o'clock position one day, the 3 o'clock the next, then 6 o'clock, and finally 9 o'clock
No guesswork just clinically guided treatment
Despite having sensitive, combination-oily skin, this cream didnt cause any irritation or make me break out